Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
J Biol Chem, 2009
December 5 Product: AstraZenecas Imfinzi Indication: Limited-stage small cell lung cancer AstraZeneca on Wednesday successfully expanded the label of its PD-L1 blocker Imfinzi (durvalumab), notching the FDAs greenlight for its use in patients with limited-stage small cell lung cancer who have not progressed after concurrent platinum chemotherapy and radiation therapy
The FDA approves drugs for safety, quality, potency, and bioequivalence to ensure a products effectiveness in reaching its intended target or disease state
Frete grtis para SP Capital e Grande SP
(Netherlands) as the platform operator and STR.VERT CONSULTANTS LTD (Cyprus) as the product seller
10.1016/j.yjmcc.2024.09.001 45
US$ 22.36
US$ 23.98
US$ 26.15
US$ 20.30
US$ 28.78
